Texas sues Tylenol makers J&J and Kenvue, claiming they hid drug's autism risks

Texas Attorney General Ken Paxton has sued Johnson & Johnson and its former unit Kenvue, alleging they concealed Tylenol's purported links to autism and ADHD when used during pregnancy, violating deceptive trade practices and fraudulent transfer laws. Kenvue, which maintains Tylenol is safe, stated it would defend against the lawsuit, while J&J asserted Kenvue's responsibility for liabilities. This legal action, alongside hundreds of private lawsuits and the FDA's move to seek new warning labels for acetaminophen, has impacted the companies' stock, with Kenvue shares falling 3.8% and J&J shares down 1.8% on the news, reflecting ongoing concerns about product liability.

Analysis

Texas Attorney General Ken Paxton has sued Johnson & Johnson (JNJ) and Kenvue (KVUE), alleging concealment of Tylenol's links to autism/ADHD and violations of deceptive trade practices and fraudulent transfer laws. This legal action led to Kenvue shares closing down 3.8% ($0.57) at $14.51 and JNJ shares falling 1.8% ($3.37) to $186.93. Kenvue has already declined over 20% since September 22, reflecting heightened market sensitivity to these claims.

The lawsuit intensifies a challenging legal and regulatory landscape for acetaminophen, following the U.S. FDA's recent announcement to seek new warning labels for potential neurodevelopmental disorder links. Hundreds of private lawsuits are also ongoing, with an appeal scheduled for November 17. Kenvue maintains Tylenol's safety and will defend the suit, while JNJ asserts Kenvue's responsibility for all post-spin-off liabilities.

Paxton's fraudulent transfer claim against JNJ, alleging the Kenvue spin-off was to shield liability, introduces a significant financial risk, potentially impacting the separation agreement. This litigation, alongside JNJ's existing talc liabilities, underscores persistent product liability challenges. The political context of the lawsuit may further amplify public and regulatory scrutiny on both companies.

Key Decisions for Investors

• Closely monitor the Texas lawsuit's progression, especially the fraudulent transfer claim against JNJ, as it could redefine liability exposure post-Kenvue spin-off.
• Evaluate Kenvue's financial resilience against mounting litigation and potential regulatory changes from the FDA's warning label initiative.
• Consider the broader implications for product liability risk across the consumer health sector, particularly for companies with similar spin-off structures.